Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill targets blood cancers in early human trial

NCT ID NCT07064122

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called AZD2962, which blocks a protein called IRAK4 involved in cancer growth. The study includes about 72 people with certain blood cancers (myelodysplastic syndromes or chronic myelomonocytic leukemia) that have not responded to prior treatments. Researchers are giving the drug as a daily pill, either alone or with other medicines, to check its safety, find the right dose, and see if it helps shrink the cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AZD2962 (an IRAK4 inhibitor taken as a pill)
What this could lead to
If successful, this could point toward a new treatment option for certain blood cancers that have stopped responding to standard therapies.
What could go wrong
This is a very early (Phase 1/2) and small trial (72 people). The drug may not work or may cause side effects. It is too soon to know if it will be safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 110 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Participants with relapsed/refractory MDS or participants with relapsed/refractory dysplastic CMML, with peripheral blasts or bone marrow blasts \< 20%, and who received one or more prior lines of therapy as per standard of care (or who exhausted locally available treatments including treatments for actionable mutations). Diagnosis must be histologically confirmed as per the WHO 2016 classification of myeloid neoplasms. 2. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2. 3. Participants must have symptomatic disease that requires therapy and allows for objective efficacy assessments. 4. Willing to provide baseline bone marrow aspirate (or biopsy if dry-tap). 5. Contraceptive use by participants or participant partners should be consistent with local regulations and also comply with Clinical Study Protocol requirements. 6. All women of childbearing potential must have a negative serum pregnancy test result at Screening. Key Exclusion Criteria: 1. Prior treatment with IRAK inhibitors or inhibitors of the inflammasome pathway. 2. Received any antineoplastic therapy (except hydroxyurea) within 15 days prior to first dose. 3. Received any strong or moderate Cytochrome P450 3A (CYP3A) inhibitors within 15 days prior to first dose. 4. Received major surgery within 28 days prior to first dose, or still recovering from surgery. 5. Received drugs that are known to prolong corrected QT interval (QTc) and with known risk of Torsades de Pointes, within 15 days prior to first dose. 6. Received immunosuppressive medications (including Graft-Versus-Host Disease prophylaxis) within 28 days prior to first dose, or within 15 days in the case of systemic steroids (doses exceeding 10 mg/day of prednisone or equivalent). 7. Received live attenuated vaccines within 28 days prior to first dose. 8. Active major bleeding event. 9. Any evidence of systemic disease, significant clinical disorder, or laboratory finding that make undesirable the participation in the study. 15\. Mean resting corrected QT interval using Fridericia's formula (QTcF) \> 450 ms obtained from triplicate Electrocardiograms (ECGs) and averaged, recorded within 5 minutes. In the presence of bundle branch block, QTcF \> 470 ms is applicable. 16\. History of intracranial bleeding within 6 months prior to first dose. 17. Active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism or excretion of oral therapy. 18\. History of a prior non-haematologic neoplasm (with some exceptions). 19. Unresolved Grade \> 2 toxicities from prior anticancer therapies (with some exceptions). 20\. Concurrent enrolment in another clinical study (with some exceptions). 21. Known hypersensitivity to study intervention or its excipients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dysplastic chronic myelomonocytic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic myelomonocytic leukemia hematopoietic and lymphoid cell neoplasm hereditary sensory and autonomic neuropathy myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Haematologic neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    18 sites in 6 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    NOT_YET_RECRUITING

    Miami, Florida, 33136, United States

  • Research Site

    RECRUITING

    Tampa, Florida, 33612, United States

  • Research Site

    RECRUITING

    Houston, Texas, 77030, United States

  • Research Site

    RECRUITING

    Heidelberg, 3084, Australia

  • Research Site

    RECRUITING

    Melbourne, 3000, Australia

  • Research Site

    RECRUITING

    Shinagawa-ku, 141-0022, Japan

  • Research Site

    RECRUITING

    Yoshida-gun, 910-1193, Japan

  • Research Site

    WITHDRAWN

    Seoul, 05505, South Korea

  • Research Site

    WITHDRAWN

    Seoul, 3722, South Korea

  • Research Site

    RECRUITING

    Barcelona, 08035, Spain

  • Research Site

    RECRUITING

    Madrid, 28027, Spain

  • Research Site

    RECRUITING

    Madrid, 28033, Spain

  • Research Site

    RECRUITING

    Pamplona, 31008, Spain

  • Research Site

    RECRUITING

    Salamanca, 37007, Spain

  • Research Site

    WITHDRAWN

    Valencia, 46026, Spain

  • Research Site

    NOT_YET_RECRUITING

    Kaohsiung City, 83301, Taiwan

  • Research Site

    NOT_YET_RECRUITING

    Tainan, 70403, Taiwan

  • Research Site

    RECRUITING

    Taipei, 100, Taiwan

  • Research Site

    RECRUITING

    London, SE5 9RS, United Kingdom

  • Research Site

    RECRUITING

    London, W1T 7HA, United Kingdom

  • Research Site

    RECRUITING

    Manchester, M20 4BX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.